
Viking Therapeutics reports Q3 2026 results, $960M cash runway
Viking Therapeutics announced a Q3 loss, a $960 million cash cushion, and accelerated obesity trial activity for its VK2735 program.

Viking Therapeutics announced a Q3 loss, a $960 million cash cushion, and accelerated obesity trial activity for its VK2735 program.
Cryptocurrencies In this article, we will review AMP's potential to reach significant values such as 1 dollar or 50 cents, analyzing current metrics…

80,834 USD on October 28, 2026. Price moved +1.54% from the previous data point.

Samsung unveils a multi‑million dollar plan that supports local schools, nonprofits and a new chip fab, promising a tech‑driven boom for Taylor,…

North Dakota opens an interactive window onto its $15 billion Legacy Fund, letting residents track every investment.

Israel’s central bank warns that a crypto work‑around cannot shield the economy from possible sanctions, sparking fierce debate ahead of elections.

Mastering altcoin cycle investing for a winning strategy

A practical guide to crypto sanctions compliance for retail and professional investors

Ohio voters will decide whether a corporate outsider or a health‑care veteran becomes the next governor amid soaring campaign costs.

Most people believe their community deserves investment, but far fewer expect local leaders to heed their suggestions, a gap echoed by UK…

Naturopathy programs now qualify as professional degrees, unlocking higher federal loan limits.